Web of Science: 0 citas, Scopus: 1 citas, Google Scholar: citas
Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
Egmond, Elfi (Universitat Autònoma de Barcelona. Departament de Psicologia Clínica i de la Salut)
Mariño, Zoe (Servei d'Hepatologia, Hospital Clínic de Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universitat de Barcelona, Barcelona, Spain)
Navines, Ricard (Universitat de Barcelona. Institut de Neurociències,)
Oriolo, Giovanni (Universitat de Barcelona. Institut de Neurociències)
Pla, Anna (Servei d'Hepatologia, Hospital Clínic de Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universitat de Barcelona, Barcelona, Spain)
Bartres, Concepció (Servei d'Hepatologia, Hospital Clínic de Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universitat de Barcelona, Barcelona, Spain)
Lens, Sabela (Servei d'Hepatologia, Hospital Clínic de Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universitat de Barcelona, Barcelona, Spain)
Forns, Xavier (Servei d'Hepatologia, Hospital Clínic de Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universitat de Barcelona, Barcelona, Spain)
Martin-Santos, Rocio (Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Ribeirão Preto, Brazil)

Fecha: 2019
Resumen: Depression has been associated with hepatitis C, as well as with its treatment with proinflammatory cytokines (i. e. , interferon). The new direct-acting antiviral agents (DAAs) have minimal adverse effects and high potency, with a direct inhibitory effect on non-structural viral proteins. We studied the incidence and associated factors of depression in a real-life prospective cohort of chronic hepatitis C patients treated with the new DAAs. The sample was recruited from a cohort of 91 patients with hepatitis C, of both sexes, with advanced level of fibrosis and no HIV coinfection, consecutively enrolled during a 6-month period for DAA treatment; those euthymic at baseline (n=54) were selected. All were evaluated through the depression module of the Patient Health Questionnaire (PHQ-9-DSM-IV), at three time points: baseline, 4 weeks, and end-of-treatment. The cumulative incidence (95%CI) of major depression and any depressive disorder during DAA treatment was 13% (6. 4-24. 4) and 46. 3% (33. 7-59. 4), respectively. No differences were observed between those patients with and without cirrhosis or ribavirin treatment (p > 0. 05). Risk factors for incident major depression during DAA treatment included family depression (relative risk 9. 1 [1. 62-51. 1]), substance use disorder (11. 0 [1. 7-73. 5]), and baseline PHQ-9 score (2. 1 [1. 1-3. 1]). The findings of this study highlight the importance of screening for new depression among patients receiving new DAAs, and identify potential associated risk factors.
Nota: Número d'acord de subvenció ISCIII/PI15/00151
Derechos: This is an article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Creative Commons
Lengua: Anglès
Documento: article ; publishedVersion
Materia: Depression ; Direct-acting antivirals ; DAA ; Hepatitis C ; PHQ-9
Publicado en: Brazilian Journal of Psychiatry, Vol. 42 (july 2019) , p. 72-76, ISSN 1809-452X

DOI: 10.1590/1516-4446-2018-0336
PMID: 31314868


5 p, 96.2 KB

El registro aparece en las colecciones:
Artículos > Artículos publicados

 Registro creado el 2020-07-06, última modificación el 2020-08-02



   Favorit i Compartir